Co-delivery of doxorubicin hydrochloride and verapamil hydrochloride by pH-sensitive polymersomes for the reversal of multidrug resistance

nuannuan li,pei zhang,chunzhi huang,yunmei song,sanjay garg,yuxia luan
DOI: https://doi.org/10.1039/c5ra15313a
IF: 4.036
2015-01-01
RSC Advances
Abstract:In this paper, we synthesized the pH-sensitive and biodegradable amphiphilic polypeptide-based block copolymer methoxy-poly(ethylene glycol)(2K)-poly(3-caprolactone)(4K)-poly(glutamic acid)(1K) (mPEG(2K)-PCL4K-PGA(1K)). mPEG(2K)-PCL4K-PGA(1K) had low critical aggregation concentration and could self-assemble into polymersomes in aqueous solution revealed by transmission electron microscopy. Therefore, two hydrophilic drug doxorubicin hydrochloride (DOX) and verapamil hydrochloride (VER) were encapsulated into the mPEG(2K)-PCL4K-PGA(1K) polymersomes to form poly(DOX + VER) co-delivery system to reverse the multidrug resistance by inhibiting the expression of P-glycoprotein and improve the anti-cancer effect of DOX. The in vitro cytotoxicity experiments indicated the obviously higher inhibition ratio to MCF-7/ADR resistant cells of poly(DOX + VER) compared with that of free DOX solution and polyDOX. The release rate of the two drugs from poly(DOX + VER) were much slower than that from the free drug solutions, and their release behaviors exhibited high pH-sensitive character. Furthermore, the low hemolysis ratio of mPEG(2K)-PCL4K-PGA(1K) confirmed that the copolymer could be applied for intravenous injection safely. Therefore, all these findings indicated that the co-delivery of DOX and VER by mPEG(2K)-PCL4K-PGA(1K) polymersomes is very promising for cancer therapy.
What problem does this paper attempt to address?